The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry

American Journal of Clinical Pathology

Volumn 112, Issue 4, 1999, Pages 513-523

  Shulman, Howard M ^a   Wells, Denise ^b   Gooley, Ted ^a   Myerson, David ^a   Bryant, Eileen ^a   Loken, Michael R ^b  

^a USA   (United States)

^b Department of Hematologics ^*  (United States)

Author keywords

Automated hematology analyzer; Bone marrow transplantation; Graft vs leukemia; Hematopoietic cell transplantation; In situ hybridization; Leukemic relapse; Manual smear differentials; Minimal residual disease; Multidimensional flow cytometry

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLAST CELL; BLOOD SMEAR; CANCER RECURRENCE; CELL SELECTION; CHILD; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LEUKEMIA; MALE; PRIORITY JOURNAL; STEM CELL;

EID: 0033491744     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/112.4.513     Document Type: Article

References (25)

1. Radich J, Slovak M. The laboratory evaluation of minimal residual disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd ed. Boston, MA: Blackwell; 1998:235-247.
2. Scharf S, Smith A, Hansen J, et al. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood. 1995;85:1954-1963.
3. Rupert K, Loken M, Myerson D, et al. Combination fluorescence in situ hybridization (FISH) and multidimensional flow cytometry (MDF) defines the genotype of aberrant cells in opposite sex bone marrow transplant (OSBMT) patients [abstract]. Appl Cytogenet. 1997;23:78.
4. Cross NC, Feng L, Bungey J, et al. Minimal residual disease after bone marrow transplant for chronic myeloid leukemia detected by the polymerase chain reaction. Leuk Lymphoma. 1993;11(suppl 1):39-43.
5. Elmaagacli AH, Becks HW, Beelen DW, et al. Detection of minimal residual disease and persistence of host-type hematopoiesis: a study in 28 patients after sex-mismatched, non-T cell-depleted allogeneic bone marrow transplantation for Philadelphia chromosome positive chronic myelogenous leukemia. Bone Marrow Transplant. 1995;16:823-829.
6. Wells D, Sale G, Shulman H, et al. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. Am J Clin Pathol. 1998;110:84-94.
7. van Dongen JJ, Szczepanski T, de Bruijn MA, et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther. 1996;2:121-133.
8. Krause JR. The automated white blood cell differential. Hematol Oncol Clin North Am. 1994;8:605-615.
9. Thalhammer-Scherrer R, Knöbl P, Korninger L, et al. Automated five-part white blood cell differential counts: efficiency of software-generated white blood cell suspect flags of the hematology analyzers Sysmex SE-9000, Sysmex NE-8000, and Coulter STKS. Arch Pathol Lab Med. 1997;121:573-577.
10. Fournier M, Giraeau A, Chretien MC, et al. Laboratory evaluation of the Abbott cell DYN 3500 5-part differential. Am J Clin Pathol. 1996;105:286-292.
11. Butarello M, Bullian P, Temporin V, et al. Sysmex SE-9000 hematology analyzer: performance evaluation on leukocyte differential counts using an NCCLS H20 protocol. Am J Clin Pathol. 1997;108:674-686.
12. Tanaka Y, Miyachi H, Kawada T, et al. An evaluation of automated hematology analyzers in detecting abnormal blood cells. J Clin Pathol. 1991;39:961-966.
13. Sivakumaran M, Allen B, Wood JK. Automated differential leucocyte counting on the Sysmex NE-8000 analyser. Clin Lab Haematol. 1994;16:206-207.
14. Schmitz L, McClure J, Litz C, et al. Morphologic and quantitative changes in blood and marrow cells following growth factor therapy. Am J Clin Pathol. 1994;101:67-75.
15. Combleet J, Fernandes BJ, Miers M. Streamline your automated hematology laboratory. MLO. 1997;68-73.
16. Terstappen LW, Loken MR. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol. 1990;2:229-240.
17. Loken M. Multidimensional data analysis in immunophenotyping. In: Robinson PJ, ed. Current Protocols in Cytometry. New York, NY Wiley-Liss; 1997.
18. Stelzer G, Shults K, Loken M. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci. 1993;677:265-280.
19. Borowitz M, Guenther K, Shults K, et al. Immunophenotyping of acute leukemia by flow cytometric analysis: use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol. 1993;100:534-540.
20. Sievers E, Lange B, Loken M, et al. Prediction of relapse of pediatric acute myeloid leukemia by multidimensional flow cytometry. J Natl Cancer Inst. 1996;88:1483-1488.
21. Loken MR, Shah VO, Dattilio KL, et al. Flow cytometric analysis of human bone marrow, II: normal B lymphocyte development. Blood. 1987;70:1316-1324.
22. Terstappen LW, Safford M, Loken MR. Flow cytometric analysis of human bone marrow, III: neutrophil maturation. Leukemia. 1990;4:657-663.
23. Loken, MR, Terstappen LWMM, Civin CI, et al. Flow cytometric characterization of erythroid, lymphoid and monomyeloid lineages in normal human bone marrow. In: Laerum OD, Bjerksnes R, eds. Flow Cytometry in Hematology. New York, NY: Academic Press; 1992:31-42.
24. Fefer A. Graft-versus-tumor responses. In: Thomas ED, Blue KG, Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd ed. Blackwell; 1998:316-326.
25. Wells DA, Hall MC, Shulman HM, et al. Occult B cell malignancies can be detected by three-color flow cytometry in patients with cytopenias. Leukemia. 1998;12:2015-2023.